Insulin icodec

Insulin icodec
Clinical data
Trade namesAwiqli
Pregnancy
category
  • AU: B3
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only / Schedule D
  • EU: Rx-only
Identifiers
  • (1a-21a),(1b-29b)-Insulin (human), 14a-L-glutamic acid-16b-L-histidine-25b-L-histidine-29b-(N6-(N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysine)-
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC280H435N71O87S6
Molar mass6380.33 g·mol−1

Insulin icodec, sold under the brand name Awiqli, is a medication used to treat diabetes. It is given once per week and its benefits are similar to long acting daily insulin.

It is an ultralong-acting basal insulin analogue that is developed by Novo Nordisk. It has a plasma half-life more than eight days (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.